Latest Period
Q1 2026
Security Snapshot
Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS) Institutional Ownership
CUSIP: 501147102
13F Institutional Holders and Ownership History from Q3 2017 to Q2 2026
Institutions Reporting
367
Shares (Excl. Options)
28,367,024
Price
$258.32
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value ("Common Stock")
- Symbol
- KRYS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 28,367,024
- Total 13F value
- $7,322,344,789
- Portfolio coverage rank
- 0.01%
- Share change
- -195,599
- Value change
- -$43,160,485
- Number of holders
- 367
- Shares outstanding
- 29,463,330
- SEC-reported price per share
- $371.67
- Insider filing price
- $371.67
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KRYS - Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") is tracked under CUSIP 501147102.
- 367 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 367 to 22 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,322,344,789 to $55,449,483.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 367 institutions filings for Q1 2026.
Security key
501147102
Latest holder period
Q1 2026
13F holders
367
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
KRYS full holder history
Krystal Biotech, Inc. SEC filings
Krystal Biotech, Inc. company facts
Krystal Biotech, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501147102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
KRYS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Krishnan Krish S | 12% | $906,060,757 | 3,388,283 | Krish S. Krishnan | 31 Mar 2026 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5% | $382,084,101 | 1,479,111 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| STATE STREET CORP | 4.4% | $218,154,766 | 1,278,975 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Mar 2026, 367 institutional investors reported holding 28,367,024 shares of Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS). This represents 96% of the company’s total 29,463,330 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
80%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 4,373,987 | +0.56% | 0.06% | $1,129,888,252 |
| BlackRock, Inc. | 13% | 3,940,456 | +0.07% | 0.02% | $1,017,898,595 |
| Avoro Capital Advisors LLC | 9.8% | 2,888,888 | 0% | 7.4% | $746,257,548 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9% | 1,456,727 | 0% | 0.02% | $376,301,719 |
| STATE STREET CORP | 4.5% | 1,314,434 | -2.1% | 0.01% | $339,544,591 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 1,165,324 | 0% | 0.01% | $301,026,496 |
| Soleus Capital Management, L.P. | 3.9% | 1,153,087 | +23% | 12% | $297,865,434 |
| Capital World Investors | 2.8% | 824,720 | +1.9% | 0.03% | $213,041,670 |
| Redmile Group, LLC | 2.3% | 673,505 | -0.62% | 12% | $173,979,812 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 643,975 | +5.2% | 0.01% | $166,383,833 |
| Hood River Capital Management LLC | 2.1% | 619,586 | +1% | 1.6% | $160,051,456 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 485,074 | -8.5% | 0.01% | $125,305,000 |
| Bellevue Group AG | 1.6% | 481,785 | +17% | 3% | $124,454,701 |
| Frazier Life Sciences Management, L.P. | 1.6% | 481,307 | -1.5% | 3.2% | $124,331,224 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 468,990 | -4.9% | 0.03% | $121,130,310 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.4% | 407,178 | +8.2% | 0.35% | $105,182,221 |
| FIRST TRUST ADVISORS LP | 1.2% | 350,521 | +43% | 0.06% | $90,546,584 |
| JANUS HENDERSON GROUP PLC | 0.91% | 266,659 | +22% | 0.03% | $68,878,997 |
| BANK OF AMERICA CORP /DE/ | 0.88% | 260,647 | +37% | 0% | $67,330,333 |
| NORTHERN TRUST CORP | 0.86% | 252,463 | +2% | 0.01% | $65,216,242 |
| Invesco Ltd. | 0.85% | 251,373 | +319% | 0.01% | $64,934,673 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.82% | 241,986 | -0.32% | 0.01% | $62,509,824 |
| GOLDMAN SACHS GROUP INC | 0.73% | 214,949 | -27% | 0.01% | $55,525,626 |
| MORGAN STANLEY | 0.71% | 209,082 | -5.6% | 0% | $54,010,448 |
| BRAIDWELL LP | 0.62% | 182,425 | -9.7% | 1.6% | $47,124,026 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
36
Latest
Q1 2026
Rows shown
1-25 of 36
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 149,189 | $55,449,483 | +$17,280,412 | $371.67 | 22 |
| 2026 Q1 | 28,367,024 | $7,322,344,789 | -$43,160,485 | $258.32 | 367 |
| 2025 Q4 | 28,422,312 | $7,006,810,379 | +$81,339,251 | $246.54 | 333 |
| 2025 Q3 | 27,965,722 | $4,936,825,964 | +$84,621,791 | $176.53 | 281 |
| 2025 Q2 | 27,659,439 | $3,802,977,476 | -$846,440 | $137.46 | 274 |
| 2025 Q1 | 27,342,861 | $4,929,918,497 | -$51,223,771 | $180.30 | 298 |
| 2024 Q4 | 27,774,030 | $4,351,782,009 | -$92,533,890 | $156.66 | 264 |
| 2024 Q3 | 28,280,954 | $5,147,915,246 | -$55,463,849 | $182.03 | 281 |
| 2024 Q2 | 28,529,838 | $5,239,051,095 | +$658,436,118 | $183.64 | 245 |
| 2024 Q1 | 25,223,190 | $4,487,798,716 | +$175,442,652 | $177.93 | 233 |
| 2023 Q4 | 24,418,337 | $3,029,453,570 | +$42,716,131 | $124.06 | 194 |
| 2023 Q3 | 23,797,985 | $2,760,663,293 | +$92,606,023 | $116.00 | 187 |
| 2023 Q2 | 23,039,160 | $2,704,675,917 | +$256,730,169 | $117.40 | 182 |
| 2023 Q1 | 20,979,177 | $1,678,957,589 | +$9,326,151 | $80.06 | 159 |
| 2022 Q4 | 20,961,146 | $1,660,575,264 | -$15,716,124 | $79.22 | 153 |
| 2022 Q3 | 20,879,536 | $1,455,390,527 | +$2,509,281 | $69.70 | 141 |
| 2022 Q2 | 20,782,487 | $1,364,495,044 | +$17,501,639 | $65.66 | 129 |
| 2022 Q1 | 20,551,109 | $1,367,525,309 | +$24,889,158 | $66.54 | 129 |
| 2021 Q4 | 19,309,579 | $1,350,723,574 | +$209,084,528 | $69.95 | 135 |
| 2021 Q3 | 16,287,424 | $850,358,590 | -$12,114,445 | $52.21 | 112 |
| 2021 Q2 | 16,400,636 | $1,115,239,700 | -$7,228,383 | $68.00 | 113 |
| 2021 Q1 | 16,474,358 | $1,268,577,569 | +$201,515,888 | $77.04 | 113 |
| 2020 Q4 | 13,913,023 | $835,272,340 | -$16,214,267 | $60.00 | 107 |
| 2020 Q3 | 14,383,109 | $619,123,442 | +$11,279,105 | $43.05 | 98 |
| 2020 Q2 | 14,124,381 | $585,026,548 | +$106,373,347 | $41.42 | 108 |